Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website
Subscribe CustomBlackClose

Belt & Road Weekly Subscription Form

download_pop

Research ReportCustomBlackClose

The full edition of the report is available at Xinhua Silk Road Database. You can click the “Table of Content” to have a general understanding of it.

Click on the button below to create your account and get immediate access to thousands of articles.

Start a Free Trial

Xinhua Silk Road
Company

Pharmaron (300759.SZ) to buy out Allergan Biologics Limited for USD120 mln

March 01, 2021


Abstract : Pharmaron (300759.SZ) announced on Monday to buy a 100-percent stake held by AGN Sundry LLC in the Allergan Biologics Limited (ABL) for about 120 million U.S. dollars.

Pharmaron.png

BEIJING, March 1 (Xinhua) -- Pharmaron (300759.SZ) announced on Monday to buy a 100-percent stake held by AGN Sundry LLC in the Allergan Biologics Limited (ABL) for about 120 million U.S. dollars. 

The Shenzhen-listed company will use its own funds to increase the capital of its wholly-owned subsidiary Pharmaron (Hong Kong) International Limited. It will buy the 100-percent equity of the ABL through the Pharmaron Biologics (UK) Holdings Limited, a wholly-owned subsidiary of the Hong Kong-based company. 

After completion of the transaction, the listed company will hold a 100-percent stake in the ABL through the Pharmaron Biologics (UK) Holdings Limited.

The transaction is expected to close in the second quarter of 2021, subject to the satisfaction of customary closing conditions, according to the Shenzhen-listed company on its official website.

The ABL consists of a state-of-the-art, flexible cGMP biomanufacturing facility located in Liverpool, United Kingdom with over 150 staff. 

Founded in 2004, Pharmaron is a cutting-edge, fully integrated pharmaceutical R&D service platform supporting the life science industry. With operations in China, the U.S. and the UK staffed by more than 11,000 employees, Pharmaron has an excellent track record in delivering end-to-end R&D solutions to its partners globally and enabling them to accelerate their novel drug discovery and development process, according to its official website. (Edited by Hu Pingchao with Xinhua Silk Road, hupingchao@xinhua.org)

Scan the QR code and push it to your mobile phone

Keyword: outbound investment Pharmaron

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to [email protected] and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial

Ask Us A Question belt & road login close

If you have any questions, please enter them in the box below.

Identifying code Reload

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to silkroadweekly@xinhua.org and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial